HUP0100350A2 - A prosztatarák kezelésére alkalmazható konjugátumok, azokat hatóanyagként tartalmazó gyógyászati készítmények, elárás ezek előállítására, valamint alkalmazásuk - Google Patents

A prosztatarák kezelésére alkalmazható konjugátumok, azokat hatóanyagként tartalmazó gyógyászati készítmények, elárás ezek előállítására, valamint alkalmazásuk

Info

Publication number
HUP0100350A2
HUP0100350A2 HU0100350A HUP0100350A HUP0100350A2 HU P0100350 A2 HUP0100350 A2 HU P0100350A2 HU 0100350 A HU0100350 A HU 0100350A HU P0100350 A HUP0100350 A HU P0100350A HU P0100350 A2 HUP0100350 A2 HU P0100350A2
Authority
HU
Hungary
Prior art keywords
treatment
prostate cancer
preparation
pharmaceutical compositions
conjugates
Prior art date
Application number
HU0100350A
Other languages
English (en)
Inventor
Stephen F. Brady
Dong-Mei Feng
Victor M. Garsky
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0100350A2 publication Critical patent/HUP0100350A2/hu
Publication of HUP0100350A3 publication Critical patent/HUP0100350A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát a szabad prosztataspecifikus antigén(PSA) által proteolitikusan specifikusan hasítható aminosav-szekvenciákat tartalmazó oligopeptideket, valamint ismert citotoxikushatóanyagokat tartalmazó konjugátumok képezik. A találmány szerintikonjugátumok citotoxikus hatóanyagként előnyösen vina-alkaloidottartalmaznak. A találmány szerinti konjugátumok prosztatarák ésjóindulatú prosztata-hipertrófia kezelésére alkalmazhatók. Ó
HU0100350A 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use HUP0100350A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
HUP0100350A2 true HUP0100350A2 (hu) 2001-08-28
HUP0100350A3 HUP0100350A3 (en) 2001-09-28

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100350A HUP0100350A3 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use

Country Status (26)

Country Link
US (2) US20060148718A1 (hu)
EP (1) EP1036093A1 (hu)
JP (1) JP2001525337A (hu)
KR (1) KR100580137B1 (hu)
CN (1) CN1181092C (hu)
AR (1) AR016427A1 (hu)
AU (1) AU744652B2 (hu)
BG (1) BG65486B1 (hu)
BR (1) BR9815116A (hu)
CA (1) CA2311615A1 (hu)
DZ (1) DZ2665A1 (hu)
EA (1) EA002745B1 (hu)
EE (1) EE200000333A (hu)
HR (1) HRP20000367A2 (hu)
HU (1) HUP0100350A3 (hu)
ID (1) ID24735A (hu)
IL (1) IL136167A0 (hu)
IS (1) IS5502A (hu)
NO (1) NO20002804L (hu)
NZ (1) NZ504615A (hu)
PE (1) PE20000009A1 (hu)
PL (1) PL197006B1 (hu)
SK (1) SK8282000A3 (hu)
TR (1) TR200002260T2 (hu)
TW (1) TW577897B (hu)
WO (1) WO1999028345A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773420B2 (en) * 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
CN105229742A (zh) 2013-04-30 2016-01-06 惠普发展公司，有限责任合伙企业 存储器访问速率
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
CA2265476A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
NO20002804L (no) 2000-07-21
CN1181092C (zh) 2004-12-22
JP2001525337A (ja) 2001-12-11
BG104563A (en) 2001-04-30
PE20000009A1 (es) 2000-01-27
TR200002260T2 (tr) 2000-12-21
CA2311615A1 (en) 1999-06-10
BR9815116A (pt) 2000-10-10
NZ504615A (en) 2003-05-30
ID24735A (id) 2000-08-03
TW577897B (en) 2004-03-01
PL197006B1 (pl) 2008-02-29
HRP20000367A2 (en) 2000-12-31
EP1036093A1 (en) 2000-09-20
KR20010032687A (ko) 2001-04-25
US20070021350A1 (en) 2007-01-25
EA002745B1 (ru) 2002-08-29
SK8282000A3 (en) 2000-11-07
PL340768A1 (en) 2001-02-26
EA200000603A1 (ru) 2000-12-25
WO1999028345A1 (en) 1999-06-10
AU1612399A (en) 1999-06-16
IS5502A (is) 2000-05-19
HUP0100350A3 (en) 2001-09-28
BG65486B1 (bg) 2008-09-30
EE200000333A (et) 2001-08-15
AR016427A1 (es) 2001-07-04
US20060148718A1 (en) 2006-07-06
NO20002804D0 (no) 2000-05-31
IL136167A0 (en) 2001-05-20
DZ2665A1 (fr) 2003-03-22
AU744652B2 (en) 2002-02-28
CN1284086A (zh) 2001-02-14
KR100580137B1 (ko) 2006-05-16

Similar Documents

Publication Publication Date Title
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
HUP0100350A2 (hu) A prosztatarák kezelésére alkalmazható konjugátumok, azokat hatóanyagként tartalmazó gyógyászati készítmények, elárás ezek előállítására, valamint alkalmazásuk
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BRPI0115953B8 (pt) complexos de derivados de fosfato
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
PT771209E (pt) Novos peptideos
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
AU2002305099A1 (en) Fatty alcohol drug conjugates
HUP0301349A2 (hu) IL-11-tartalmú készítmények
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE256473T1 (de) Konjugate welche bei der behandlung von prostatakrebs nützlich sind
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
IL158433A (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
TR201910060T4 (tr) SYN3 bileşimleri ve yöntemleri.
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
WO1999044628A8 (en) Conjugates useful in the treatment of prostate cancer
ECSP982763A (es) Conjugados utiles en el tratamiento de cancer de prostata